Genentech, Inc.
NEWS
Developed initially to deliver cytotoxic payloads to tumors, antibody therapeutics are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer.
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody, Tecentriq, for metastatic bladder cancer.
BioSpace’s 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
Genentech made approximately 35 presentations at ECTRIMS involving blockbuster MS drug Ocrevus drug, with a focus on relapsing-remitting MS and continuing safety studies.
Two Phase III trials of Genentech (Roche)'s Vabysmo hit the primary endpoint in macular edema caused by branch and central retinal vein occlusion, showing non-inferiority to Regeneron’s Eylea.
The World Muscle Society 2022 Congress is ongoing in Halifax, Canada, with numerous companies presenting cutting-edge research in neuromuscular diseases. Here’s a look.
Genentech and privately-held Arsenal Biosciences forged a multi-year collaboration to identify critical success circuits in T cell-based therapies for solid tumors.
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.
In the second half of the calendar year, the biopharma industry continues to ascend in mergers and acquisitions, new drug approvals and big investments, indicate market confidence and growth.
JOBS
IN THE PRESS